Söderberg-Nauclér, 2014 - Google Patents
Treatment of cytomegalovirus infections beyond acute disease to improve human healthSöderberg-Nauclér, 2014
- Document ID
- 15460619710407020034
- Author
- Söderberg-Nauclér C
- Publication year
- Publication venue
- Expert review of anti-infective therapy
External Links
Snippet
Human cytomegalovirus is a common virus that establishes latency and persistence after a primary infection in 50–90% of populations worldwide. In otherwise healthy persons, the infection is generally mild or asymptomatic, although it may cause mononucleosis …
- 206010011831 Cytomegalovirus infection 0 title abstract description 86
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Söderberg-Nauclér | Treatment of cytomegalovirus infections beyond acute disease to improve human health | |
| Rasche et al. | EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT | |
| Cobbs | Cytomegalovirus and brain tumor: epidemiology, biology and therapeutic aspects | |
| Bollard et al. | How I treat T-cell chronic active Epstein-Barr virus disease | |
| Henrich et al. | HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study | |
| Lu et al. | CD4: CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV‐positive patients | |
| Krishna et al. | Transient activation of human cytomegalovirus lytic gene expression during latency allows cytotoxic T cell killing of latently infected cells | |
| Spivak et al. | Ex vivo bioactivity and HIV-1 latency reversal by ingenol dibenzoate and panobinostat in resting CD4+ T cells from aviremic patients | |
| Bouchat et al. | Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV‐1 | |
| Coleman et al. | Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines | |
| Kotton | Management of cytomegalovirus infection in solid organ transplantation | |
| Fonseca et al. | Adenovirus evasion of interferon-mediated innate immunity by direct antagonism of a cellular histone posttranslational modification | |
| Carbone et al. | HIV-associated lymphomas and gamma-herpesviruses | |
| Bustamante et al. | Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease | |
| Shahbaz et al. | The quality of SARS-CoV-2–specific T cell functions differs in patients with mild/moderate versus severe disease, and T cells expressing coinhibitory receptors are highly activated | |
| Tse et al. | Epstein Barr virus-associated lymphoproliferative diseases: the virus as a therapeutic target | |
| Limaye et al. | CMV in critically ill patients: pathogen or bystander? | |
| Ariza-Heredia et al. | Human herpes virus 8 in solid organ transplantation | |
| Rouce et al. | Epstein–Barr virus lymphoproliferative disease after hematopoietic stem cell transplant | |
| Meisel et al. | Cytomegalovirus infection impairs immunosuppressive and antimicrobial effector functions of human multipotent mesenchymal stromal cells | |
| Poole et al. | Human cytomegalovirus latency: targeting differences in the latently infected cell with a view to clearing latent infection | |
| Hamilton et al. | Human cytomegalovirus directly modulates expression of chemokine CCL2 (MCP-1) during viral replication | |
| Cartwright et al. | Initiation of antiretroviral therapy restores CD4+ T memory stem cell homeostasis in simian immunodeficiency virus-infected macaques | |
| Kakalacheva et al. | Intrathymic epstein‐barr virus infection is not a prominent feature of myasthenia gravis | |
| Sebastian et al. | Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions |